Arterial embolization in management of massive bleeding from gastric and duodenal ulcers

2001 ◽  
Vol 53 (5) ◽  
pp. AB222
2011 ◽  
Vol 22 (7) ◽  
pp. 911-916 ◽  
Author(s):  
Ikushima Ichiro ◽  
Higashi Shushi ◽  
Ishii Akihiko ◽  
Iryo Yasuhiko ◽  
Yamashita Yasuyuki

Endoscopy ◽  
1995 ◽  
Vol 27 (04) ◽  
pp. 304-307 ◽  
Author(s):  
H. Toyoda ◽  
S. Nakano ◽  
I. Takeda ◽  
T. Kumada ◽  
K. Sugiyama ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-5
Author(s):  
Gang Li ◽  
Lin Gao ◽  
Jing Zhou ◽  
Bo Ye ◽  
Jingzhu Zhang ◽  
...  

Objective. To describe the management and prognosis of splenic abscess after splenic arterial embolization in severe acute pancreatitis (SAP) patients.Methods. This is a retrospective observational study. From August 2012 to August 2017, SAP patients with infected pancreatic necrosis (IPN) who underwent splenic arterial embolization after massive hemorrhage of the splenic artery were screened and those who developed splenic abscess were included for analysis. The demographic characteristics, etiology, treatment of splenic abscess, and clinical outcomes of these cases were collected and analyzed.Results. A total of 18 patients with splenic abscess formed after splenic arterial embolization were included for data analysis. The median age of the 18 patients was 46 years. The etiologies included biliary AP, hypertriglyceridemic AP (HTG-AP), and other causes. Ten patients underwent minimally invasive percutaneous drainage only for splenic abscess while the other eight patients received splenectomy. One patient died due to uncontrolled infection and another patient died due to massive bleeding, and the remaining sixteen patients survived.Conclusion. The incidence of splenic abscess was high in patients requiring splenic arterial embolization due to massive bleeding. Our data showed that most splenic abscess could be successfully managed with minimally invasive interventions, and traditional splenectomy should serve as a backup treatment.


2002 ◽  
Vol 168 (7) ◽  
pp. 384-390 ◽  
Author(s):  
Mikael Ljungdahl ◽  
Lars-Gunnar Eriksson ◽  
Rickard Nyman ◽  
Sven Gustavsson

Biomedicines ◽  
2019 ◽  
Vol 7 (3) ◽  
pp. 54 ◽  
Author(s):  
Hideaki Kawabata ◽  
Misuzu Hitomi ◽  
Shigehiro Motoi

Bleeding from unresectable gastric cancer (URGC) is not a rare complication. Two major ways in which the management of this issue differs from the management of benign lesions are the high rate of rebleeding after successful hemostasis and that not only endoscopic therapy (ET) and transcatheter arterial embolization (TAE) but palliative radiotherapy (PRT) can be applied in the clinical setting. However, there are no specific guidelines concerning the management of URGC with bleeding. We herein discuss strategies for managing bleeding from URGC. A high rate of initial hemostasis for active bleeding is expected when using various ET modalities properly. If ET fails in patients with hemostatic instability, emergent TAE is considered in order to avoid a life-threating condition due to massive bleeding. Early PRT, especially, regimens with a high biologically effective dose (BED) of ≥39 Gy should be considered not only for patients with hemostatic failure but also for those with successful hemostasis and inactive hemorrhage, as longer duration of response with few complications can be expected. Further prospective, comparative studies considering not only the hemostatic efficacy of these modalities but the patients’ quality of life are needed in order to establish treatment strategies for bleeding from URGC.


2020 ◽  
pp. 1-11
Author(s):  
Markus Mille ◽  
Thomas Engelhardt ◽  
Albrecht Stier

<b><i>Background:</i></b> Acute peptic ulcer bleeding is still a major reason for hospital admission. Especially the management of bleeding duodenal ulcers needs a structured therapeutic approach due to the higher morbidity and mortality compared to gastric ulcers. Patient with these bleeding ulcers are often in a high-risk situation, which requires multidisciplinary treatment. <b><i>Summary:</i></b> This review provides a structured approach to modern management of bleeding duodenal ulcers and elucidates therapeutic practice in high-risk situations. Initial management including pharmacologic therapy, risk stratification, endoscopy, surgery, and transcatheter arterial embolization are reviewed and their role in the management of bleeding duodenal ulcers is critically discussed. Additionally, a future perspective regarding prophylactic therapeutic approaches is outlined. <b><i>Key Messages:</i></b> Beside pharmacotherapeutic and endoscopic advances, bleeding management of high-risk duodenal ulcers is still a challenge. When bleeding persists or rebleeding occurs and the gold standard endoscopy fails, surgical and radiological procedures are indicated to manage ulcer bleeding. Surgical procedures are performed to control hemorrhage, but they are still associated with a higher morbidity and a longer hospital stay. In the meantime, transcatheter arterial embolization is recommended as an alternative to surgery and more often replaces surgery in the management of failed endoscopic hemostasis. Future studies are needed to improve risk stratification and therefore enable a better selection of high-risk ulcers and optimal treatment. Additionally, the promising approach of prophylactic embolization in high-risk duodenal ulcers has to be further investigated to reduce rebleeding and improve outcomes in these patients.


Sign in / Sign up

Export Citation Format

Share Document